Zacks Investment Research on MSN
Recursion Pharmaceuticals (RXRX) down 16.5% since last earnings report: Can it rebound?
A month has gone by since the last earnings report for Recursion Pharmaceuticals (RXRX). Shares have lost about 16.5% in that time frame, underperforming the S&P 500. Will the recent negative trend ...
Recursion (Nasdaq: RXRX) said on Wednesday that it had named Vicki Goodman as chief medical officer, effective April 6, 2026, succeeding David Mauro. Goodman had more than two decades of experience in ...
Recursion on Tuesday announces top-line results of the SYCAMORE trial, studying REC-994 in symptomatic CCM patients. REC-994 met its primary endpoint of safety and tolerability, but there were not yet ...
Recursion Pharmaceuticals , Inc. (NASDAQ:RXRX), currently trading at $4.32 and showing signs of being undervalued according to InvestingPro Fair Value metrics, has announced the filing of a prospectus ...
SALT LAKE CITY and TORONTO and MONTRÉAL, May 08, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results